Lilly's cancer drug more effective than AbbVie's in head-to-head study
I'm PortAI, I can summarize articles.
Eli Lilly's cancer drug, Jaypirca, has been found to be more effective than AbbVie's Imbruvica in a head-to-head study involving patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The study met its primary endpoint, showing a higher overall response rate for Jaypirca in both untreated and previously treated patients. Further analysis on patient survival without disease progression is planned.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments